4-[3-(4-methyl-1H-benzimidazol-2-yl)-3-oxoprop-1-enyl]-N-(1H-pyrrol-2-yl)benzamide
C22H18N4O2 — CID 156700158
Data last refreshed: (MolForge compound catalog, from PubChem)
About 4-[3-(4-methyl-1H-benzimidazol-2-yl)-3-oxoprop-1-enyl]-N-(1H-pyrrol-2-yl)benzamide
4-[3-(4-methyl-1H-benzimidazol-2-yl)-3-oxoprop-1-enyl]-N-(1H-pyrrol-2-yl)benzamide (PubChem CID 156700158) has the molecular formula C22H18N4O2 and a molecular weight of 370.41 g/mol. Its IUPAC name is 4-[3-(4-methyl-1H-benzimidazol-2-yl)-3-oxoprop-1-enyl]-N-(1H-pyrrol-2-yl)benzamide.
Molecular Properties
| Compound Name | 4-[3-(4-methyl-1H-benzimidazol-2-yl)-3-oxoprop-1-enyl]-N-(1H-pyrrol-2-yl)benzamide |
|---|---|
| PubChem CID | 156700158 |
| Molecular Formula | C22H18N4O2 |
| Molecular Weight | 370.41 g/mol |
| Exact Mass | 370.14 |
| IUPAC Name | 4-[3-(4-methyl-1H-benzimidazol-2-yl)-3-oxoprop-1-enyl]-N-(1H-pyrrol-2-yl)benzamide |
| SMILES | Cc1cccc2[nH]c(C(=O)C=Cc3ccc(C(=O)Nc4ccc[nH]4)cc3)nc12 |
| InChI | InChI=1S/C22H18N4O2/c1-14-4-2-5-17-20(14)26-21(24-17)18(27)12-9-15-7-10-16(11-8-15)22(28)25-19-6-3-13-23-19/h2-13,23H,1H3,(H,24,26)(H,25,28) |
| InChIKey | RRYZDUQNYBZRIB-UHFFFAOYSA-N |
| XLogP | 4.35 |
| TPSA | 90.64 Ų |
| H-Bond Donors | 3 |
| H-Bond Acceptors | 3 |
| Rotatable Bonds | 5 |
| Heavy Atoms | 28 |
| Complexity | — |
Lipinski Rule of Five
Passes Rule of Five
| Rule | Value |
|---|---|
| MW ≤ 500 | 370.41 |
| LogP ≤ 5 | 4.35 |
| H-Bond Donors ≤ 5 | 3 |
| H-Bond Acceptors ≤ 10 | 3 |
Computed Properties (RDKit)
| Structural Alerts | {'alert_name': 'Michael_acceptor_1', 'substructure': 'N/A'} |
|---|
Frequently Asked Questions
Browse: Molecules A–Z · all molecules A–Z · drugs A–Z · protein targets A–Z.
Sources
- PubChem CID 156700158 — identifiers, structure, computed properties (public domain)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.